SGLT2s beat GLP‑1s for CKD
Recent comparative analyses indicate SGLT2 inhibitors outperform GLP‑1 receptor agonists for lowering chronic kidney disease risk in people with type 2 diabetes—important when prioritizing therapies for renal protection X post. That distinction matters for patients where CKD progression is the primary concern, even if GLP‑1s excel for weight and glycemic parameters X post.
A Danish target-trial emulation enrolled 36,279 people who initiated SGLT2 inhibitors and 18,782 who started GLP‑1 receptor agonists. (jamanetwork.com) The study reported weighted 5‑year risks of chronic kidney disease of 6.7% for SGLT2 initiators versus 8.2% for GLP‑1RA initiators — an absolute difference of ~1.5 percentage points. (medicaldialogues.in) SGLT2 initiation was also associated with a lower 5‑year count of acute kidney injury events in the cohort. (jamanetwork.com) The protective signal was strongest in people without preexisting kidney disease, where subgroup analyses showed the largest relative benefit. (jamanetwork.com) Participants were metformin‑treated adults with type 2 diabetes who started the drugs between January 2014 and November 2020, with follow‑up through October 2024. (pure.au.dk) KDIGO’s 2024 guideline update expanded recommendations for SGLT2 inhibitor use to emphasize kidney protection across CKD populations, independent of diabetes status. (kdigo.org) Independent pooled analyses and network meta‑analyses that aggregated data from dozens of trials (the largest review examined 39 trials and ~100,000 patients) similarly found stronger effects of SGLT2 inhibitors than GLP‑1 RAs on kidney failure endpoints. (ajmc.com) Authors and commentators flagged limitations including the observational design, possible residual confounding, missing BMI data, and limited generalizability outside Nordic registry populations. (ajmc.com)
